Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ase Industrial Holding Ltd ADR
(NY:
ASX
)
9.840
+0.140 (+1.44%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ase Industrial Holding Ltd ADR
< Previous
1
2
3
4
5
6
7
8
Next >
Pushpay Announces Everygift™, Suite of Product Features that Enable Churches to Grow Generosity
May 16, 2023
Streamlined tools and new partnership with Engiven expands giving options and provides a seamless transaction experience for churchgoers
From
Pushpay
Via
GlobeNewswire
Metals & Mining Hybrid Virtual Investor Conference: Presentations Now Available for Online Viewing
May 12, 2023
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
ASE Technology Reports Mixed Q1 Performance, Margins Shrink
April 27, 2023
Via
Benzinga
5 Value Stocks In The Technology Sector
February 21, 2023
Via
Benzinga
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
May 15, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Appendix 4C – Q3 FY23 Quarterly Cash Flow Report
May 10, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Earnings Preview: ASE Technology Holding Co
February 08, 2023
Via
Benzinga
Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy
May 10, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
May 09, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Battery & Precious Metals Virtual Investor Conference: Presentations Now Available for Online Viewing
May 05, 2023
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
ASE wins Device Technology of the Year award for VIPack™
May 02, 2023
From
Advanced Semiconductor Engineering, Inc.
Via
Business Wire
ASE recognized for excellence by Texas Instruments
April 28, 2023
From
Advanced Semiconductor Engineering, Inc.
Via
Business Wire
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology
April 26, 2023
Wearable sensor parameters correlate strongly with clinical scales of motor impairment
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Runway Growth Finance Corp. Provides First Quarter 2023 Portfolio Update
April 06, 2023
From
Runway Growth Finance Corp.
Via
GlobeNewswire
Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
April 04, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Pushpay’s Annual State of Church Tech Report Shows Refined Use of Ministry Tools Among Catholic Churches
April 03, 2023
New results reveal the significant role that technology and digital solutions now play among parishes and diocese nationwide
From
Pushpay
Via
GlobeNewswire
Pushpay Announces New Product Innovations to Help Streamline Ministry Operations and Increase Engagement in the Church
March 30, 2023
From
Pushpay
Via
GlobeNewswire
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
March 16, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
ASE Drives Latency and Bandwidth Innovation with VIPack™ Fanout Package-on-Package
March 14, 2023
From
Advanced Semiconductor Engineering, Inc.
Via
Business Wire
Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease
March 14, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Pushpay’s Customer Success Team Wins Contact Center of the Year at the 2023 Stevie® Awards
March 10, 2023
Pushpay was recognized among three categories at the 17th annual Stevie® Awards for Sales and Customer Success
From
Pushpay
Via
GlobeNewswire
Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
March 08, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Pushpay’s 2023 State of Technology Report Reveals Hybrid Church Is Here to Stay
March 01, 2023
Research surfaces the powerful role technology and digital solutions play in the faith sector today, and future aspirations of the Church
From
Pushpay
Via
GlobeNewswire
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
February 28, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
February 23, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
February 21, 2023
From
uniQure Inc.
Via
GlobeNewswire
Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial
February 16, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Pushpay’s Women’s Leadership Exploration and Development Group to Host Public Event on International Women’s Day
February 16, 2023
“Bold Careers: Women Executives Discuss Their Authentic Journey”
From
Pushpay
Via
GlobeNewswire
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
January 30, 2023
Independent Study Reports ATH434 Prevented Onset of Motor and Non-Motor Symptoms in Animals with Genetically Induced Parkinson’s disease
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
January 25, 2023
Recruitment ongoing in Europe, Asia-Pacific, and the U.S. for study of rapidly progressive Parkinsonian Disorder
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.